Pizzuti Dana 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 21, 2025
Insider Transaction Report
Form 4
Pizzuti Dana
Chief Med and Dev Officer
Transactions
- Sale
Common Stock
2025-03-19$34.17/sh−2,388$81,598→ 72,360 total - Sale
Common Stock
2025-03-19$34.83/sh−127$4,423→ 72,233 total
Footnotes (4)
- [F1]Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F4]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.